ENVBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Enveric Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.39+0.01 (+0.72%)

Close on Oct 19, 2026

Market cap: $5.54M
P/E (TTM): –
Dividend yield: –

Enveric Biosciences, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	–	–	–	–	–	–	40	43	49	36	20	–	–	–	–	–
Cost of Revenue	–	–	–	–	–	–	32	34	38	29	13	–	–	–	–	–
Gross Profit	–	–	–	–	–	–	8.15	8.98	10	6.93	6.87	–	–	–	–	–
Research & Development	2.78	2.84	7.25	8.03	4.79	0.17	–	–	–	0.06	–	–	–	–	–	–
Selling, General & Admin	–	–	–	–	20	5.32	2.30	11	19	9.36	5.84	–	–	–	–	–
Selling & Marketing	–	–	–	–	–	–	–	–	–	0.42	0.12	–	–	–	–	–
General & Administrative	5.79	6.45	8.85	12	20	–	–	–	–	8.55	5.72	-0.03	-0.03	0.02	0.03	0.04
Operating Expenses	–	–	–	–	–	–	14	16	21	12	7.66	–	–	–	–	–
Operating Income	-8.77	-9.63	-16	-27	-65	-5.62	-2.30	-7.15	-11	-5.38	-0.79	0.03	0.03	-0.02	-0.03	-0.04
Interest Expense	–	–	–	0.01	0.01	0.45	0.08	0.73	0.58	0.75	0.24	–	–	–	–	–
Other Non-Operating Income	0.00	0.07	-0.81	7.46	8.19	-1.25	0.11	-3.40	-0.57	-1.15	-0.15	–	–	–	–	–
Merger & Restructuring Charges	–	–	1.00	–	–	–	–	–	0.40	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	5.97	29	–	8.20	9.04	0	–	–	–	–	–	–	–
Gain (Loss) on Investments	0.00	0.02	0.21	3.47	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	0.00	–	–	–	0.01	0.00	0	–	–	–	–	–	–	–
Pretax Income	-8.77	-9.57	-17	-20	-56	-6.86	-5.22	-11	-11	-6.53	–	-0.03	0.00	-0.02	-0.03	-0.04
Income Tax Expense	–	0.01	0.03	-1.49	-7.45	–	0.39	6.35	-2.39	-3.75	-0.13	0.00	0.00	0.00	0.00	0.00
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	-9.07	-2.78	-0.81	–	–	–	–	–
Minority Interest in Earnings	–	–	–	–	–	–	–	–	0	0.00	–	–	–	–	–	–
Net Income	-8.77	-9.57	-17	-18	-49	-6.86	-2.41	-17	-9.07	-2.78	-0.81	-0.03	0.00	-0.02	-0.03	-0.04
Preferred Dividends	3.36	–	0.02	0.03	–	–	0.43	2.58	2.09	0	–	–	–	–	–	–
Net Income to Common	-12	-9.57	-17	-19	-49	–	-6.03	-19	-11	-2.78	–	–	–	–	–	–
EPS (Basic)(per share)	-36.24	-228.48	-121.29	-13.00	-103.69	-59.50	-23.00	-1,023.50	-937.50	-262.50	-87.50	0.00	0.00	0.00	0.00	-12.50
EPS (Diluted)(per share)	-36.24	-228.48	-121.29	-13.00	-103.50	-59.50	-23.00	-1,023.50	-937.50	-262.50	-87.50	0.00	0.00	0.00	0.00	-12.50
Shares Outstanding (Basic, Weighted)(shares)	0.33	0.04	0.14	1.45	0.47	0.12	0.11	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Shares Outstanding (Diluted, Weighted)(shares)	0.33	0.04	0.14	1.45	0.47	0.12	0.04	0.02	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
EBITDA	-8.57	-9.29	-16	-27	-64	-5.50	-0.03	-4.24	-7.68	-4.02	-0.63	–	–	–	–	–
Net Interest Income	0.00	0.00	0.00	-0.01	–	–	–	–	–	–	0.09	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -304.0%

Financial strength

Current ratio: 10.21
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 963.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.69
Dividend yield: –